In AMBER parts 1c/1e and 2A, the safety and efficacy of the combination of cobolimab plus dostarlimab across the cobolimab 100, 300, and 900 mg doses were assessed in patients with locally advanced or metastatic melanoma, including subsets of patients who were immunotherapy-naïve and those who had progressed on prior anti–PD-(L)1 therapy. This evidence concerns the gene CD274 and metastatic melanoma.